Phase I trial of TR-1, a replacement therapy of wild type p53/p21, in patients with ovarian, breast or colon cancer.
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2016
At a glance
- Drugs TR 1 (Primary)
- Indications Breast cancer; Colon cancer; Ovarian cancer
- Focus Adverse reactions
- Sponsors Sellas Life Sciences Group
- 29 Mar 2016 According to Sellas Life Sciences media release, the company plans to initiate this study by early 2017.
- 29 Mar 2016 Planned initiation date changed from 1 Apr 2016 to 1 Jan 2017, according to Sellas Life Sciences media release.
- 11 Nov 2015 Planned initiation date changed from 1 Dec 2015 to 1 Apr 2016 according to a Sellas Life Sciences media release.